NLRP3 and COVID-19: Blocking the over-activation of the NLRP3 inflammasome and the excessive generation of its end-products or supplementing with drugs, such as r-klotho or Ang-(1-7), capable to restore the cytoprotective capacity of the endothelium should be considered pharmacological options to attenuate potential vascular sequelae derived from COVID-19.